The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Open accessAbstract
Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been devoted to the discovery of new potent inhibitors. Until now, fourteen EGFR small-molecule inhibitors have been globally approved for the treatment of different types of cancers. Although these drugs showed high efficacy in cancer therapy, EGFR mutations have emerged as a big challenge for these drugs. In this review, we focus on the EGFR small-molecule inhibitors that have been approved for clinical uses in cancer therapy. These drugs are classified based on their chemical structures, target kinases, and pharmacological uses. The synthetic routes of these drugs are also discussed. The crystal structures of these drugs with their target kinases are also summarized and their bonding modes and interactions are visualized. Based on their binding interactions with the EGFR, these drugs are also classified into reversible and irreversible inhibitors. The cytotoxicity of these drugs against different types of cancer cell lines is also summarized. In addition, the proposed metabolic pathways and metabolites of the fourteen drugs are discussed, with a primary focus on the active and reactive metabolites. Taken together, this review highlights the syntheses, target kinases, crystal structures, binding interactions, cytotoxicity, and metabolism of the fourteen globally approved EGFR inhibitors. These data should greatly help in the design of new EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“These crystal structures include the complex of neratinib into the kinase domain of the EGFR T790M mutation (pdb: 2JIV) and the EGFR T790M/L858R mutant (pdb: 3W2Q) [120,121].”
BackgroundBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 2×
“They also include the crystal structure of gefitinib bound to the mutated EGFR kinase (pdb: 2ITO, 2ITZ, 3UG2, 4I22, 5Y80, and 5Y7Z) [15,66,84,85].”
BackgroundSolca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · cited 5×
“In another study, afatinib exhibited inhibitory activity against the HER2 kinase and ErbB-4 kinase at EC50 values of 14 and 1 nM, respectively [41].”
BackgroundInfluentialFinlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636 · cited 3×
“The two metabolites showed inhibitory activity against the wild-type and mutated EGFR with kinase selectivity compared to or lower than the parent, osimertinib [131,133].”
BackgroundEGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
Li, X., Yang, C., Wan, H., Zhang, G., Feng, J., Zhang, L., Chen, X., Zhong, D., Lou, L., Tao, W., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.01.021 · Cited by 227
Kulukian, A., Lee, P., Taylor, J., Rosler, R., de Vries, P., Watson, D., Forero-Torres, A., & Peterson, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0873 · Cited by 222
Nagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Cited by
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
Self-citationShumliakivska, M., Luxán, G., Hemmerling, I., Scheller, M., Li, X., Müller-Tidow, C., Schuhmacher, B., Sun, Z., Dendorfer, A., Debes, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43003-w · Cited by 76
SHF Acts as a Novel Tumor Suppressor in Glioblastoma Multiforme by Disrupting STAT3 Dimerization
Wang, J., Huang, Z., Ji, L., Chen, C., Wan, Q., Xin, Y., Pu, Z., Li, K., Jiao, J., Yin, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202200169 · Cited by 22
Metadata
- Authors
- Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M., & Gouda, A. M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-04
- Volume
- 26
- Issue
- 21
- Pages
- 6677
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3210935050
- Cited by
- 194
- References
- 22
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.